|
Kiromic BioPharma, Inc. (KRBP): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Kiromic BioPharma, Inc. (KRBP) Bundle
Dive into the innovative world of Kiromic BioPharma, a cutting-edge biotechnology company revolutionizing cancer and autoimmune disease treatment through groundbreaking AI-driven immunotherapies. With its proprietary CRISPR gene editing technology and advanced T-cell therapies, Kiromic is pushing the boundaries of precision medicine, offering hope for patients through novel therapeutic approaches that leverage artificial intelligence and genetic engineering. Discover how this Houston-based biotech firm is transforming the landscape of cancer research and immunotherapy development in our comprehensive marketing mix analysis.
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Product
Precision Immunotherapies Development
Kiromic BioPharma specializes in developing targeted immunotherapies for cancer and autoimmune diseases, utilizing advanced technological platforms.
Technology Platform
The company employs AI-driven target discovery and CRISPR gene editing technology to engineer innovative cell therapies.
| Technology | Specific Application | Development Stage |
|---|---|---|
| TAC-NK Therapy | Cancer Immunotherapy | Preclinical/Clinical Development |
| CAR-T Cell Therapy | Cancer Treatment | Research and Development |
Product Pipeline
- Primary focus on engineered T-cell therapies
- Targeting multiple cancer indications
- Utilizing proprietary CRISPR gene editing technology
Therapeutic Approach
Kiromic's product strategy centers on developing precision immunotherapies that leverage advanced genetic engineering techniques to enhance treatment efficacy.
| Therapy Type | Target Indication | Unique Mechanism |
|---|---|---|
| TAC-NK Cells | Solid Tumors | Genetically Modified Natural Killer Cells |
| CAR-T Cells | Hematologic Cancers | Chimeric Antigen Receptor Engineering |
Technology Differentiation
The company distinguishes itself through advanced AI-driven target discovery and innovative gene editing approaches.
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Place
Headquarters and Primary Location
Kiromic BioPharma, Inc. is headquartered at 2450 Holcombe Blvd, Suite J-609, Houston, Texas 77021.
Research and Development Facilities
Primary research and development facilities are located in Houston, Texas.
| Location Type | Specific Details |
|---|---|
| Headquarters Address | 2450 Holcombe Blvd, Suite J-609, Houston, Texas 77021 |
| Research Facilities | Houston, Texas |
Market Distribution Channels
- Biotechnology and pharmaceutical research markets
- Oncology research sector
- Immunotherapy development platforms
Geographic Market Reach
Primary Market Focus: United States biotechnology research ecosystem
| Market Segment | Geographical Scope |
|---|---|
| Primary Market | United States |
| Secondary Markets | Global oncology and immunotherapy research networks |
Potential Collaboration Networks
- Academic research institutions
- Pharmaceutical development companies
- Oncology research centers
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Promotion
Scientific Conference and Medical Symposium Presentations
Kiromic BioPharma participates in key scientific events to showcase research findings:
| Conference | Date | Presentation Focus |
|---|---|---|
| American Association for Cancer Research (AACR) | April 2023 | AIR-NK™ platform technology |
| Society for Immunotherapy of Cancer (SITC) | November 2023 | Immunotherapy research developments |
Investor Relations Communication
Investor communication strategies include:
- Quarterly earnings conference calls
- Investor presentations at healthcare investment conferences
- SEC filing disclosures
Press Release and Media Engagement
| Press Release Category | Number of Releases in 2023 |
|---|---|
| Clinical Trial Updates | 4 |
| Corporate Milestones | 3 |
| Research Achievements | 2 |
Digital Communication Channels
Corporate Website Analytics (2023):
- Total Website Visitors: 42,567
- Average Time on Site: 3.2 minutes
- Unique Page Views: 127,345
Partnership and Licensing Promotion
Partnership engagement metrics:
| Partnership Type | Number of Discussions | Potential Value |
|---|---|---|
| Research Collaboration | 3 | $5.2 million |
| Licensing Opportunities | 2 | $7.8 million |
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Price
Stock Price and Market Valuation
As of January 2024, Kiromic BioPharma, Inc. (KRBP) stock price fluctuates around $0.13 per share. The company's market capitalization is approximately $7.5 million.
| Financial Metric | Value |
|---|---|
| Current Stock Price | $0.13 |
| Market Capitalization | $7.5 million |
| 52-Week Low | $0.10 |
| 52-Week High | $0.45 |
Funding Strategy
Kiromic BioPharma's pricing and financial strategy is characterized by:
- Equity offerings as primary funding mechanism
- Research grants supplementing financial resources
- Venture capital investments
Financial Performance Indicators
Recent financial data indicates:
| Financial Indicator | Amount |
|---|---|
| Total Revenue (2023) | $620,000 |
| Net Loss | $12.4 million |
| Cash and Cash Equivalents | $3.2 million |
Pricing Considerations
Biotechnology development stage pricing factors:
- Clinical trial progression
- Potential therapeutic value
- Intellectual property strength
- Competitive landscape assessment